State Board of Administration of Florida Retirement System bought a new stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Get Rating) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 12,630 shares of the company’s stock, valued at approximately $177,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new position in shares of Design Therapeutics during the 2nd quarter valued at approximately $32,000. Amalgamated Bank purchased a new position in shares of Design Therapeutics during the 1st quarter valued at approximately $63,000. SG Americas Securities LLC purchased a new position in shares of Design Therapeutics during the 2nd quarter valued at approximately $165,000. MetLife Investment Management LLC lifted its position in shares of Design Therapeutics by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 16,885 shares of the company’s stock valued at $273,000 after buying an additional 6,021 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Design Therapeutics by 28.6% during the 1st quarter. JPMorgan Chase & Co. now owns 20,239 shares of the company’s stock valued at $327,000 after buying an additional 4,504 shares in the last quarter. Hedge funds and other institutional investors own 69.34% of the company’s stock.
Design Therapeutics Stock Performance
NASDAQ DSGN opened at $14.36 on Wednesday. The business has a fifty day moving average price of $16.24 and a 200 day moving average price of $16.81. Design Therapeutics, Inc. has a one year low of $9.61 and a one year high of $26.30. The company has a market cap of $802.87 million, a P/E ratio of -14.11 and a beta of 1.51.
Analyst Ratings Changes
Design Therapeutics Profile
Design Therapeutics, Inc a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs.
- Get a free copy of the StockNews.com research report on Design Therapeutics (DSGN)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.